PDGFbeta Receptor Activation Promotes Atheroprotective Changes in SMC Phenotype
PDGFbeta 受体激活促进 SMC 表型的动脉粥样硬化变化
基本信息
- 批准号:9303020
- 负责人:
- 金额:$ 64.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2021-03-31
- 项目状态:已结题
- 来源:
- 关键词:AgeAllelesAnti-Inflammatory AgentsApolipoprotein EApoptosisArterial Fatty StreakAtherosclerosisCause of DeathCell CountCell LineageCellsClinicalCollagenDevelopmentDietEventExtracellular MatrixFoam CellsGenesGeneticGenomicsGleevecGoalsGrantHemorrhageHumanImatinibIn VitroIncidenceInflammatoryInfusion proceduresInterleukin-1 betaIntravenous infusion proceduresKnock-outKnockout MiceLeadLesionLesion by StageLipidsMechanicsMedicineMesenchymalMitogensMusMuscle CellsMyocardial InfarctionMyofibroblastNatureNecrosisPathogenesisPharmaceutical PreparationsPharmacologyPhenotypePhenylephrinePlayProbabilityProgressive DiseaseReceptor ActivationReceptor SignalingResearchResolutionRoleRuptureSignal PathwaySmooth Muscle MyocytesStem cellsStrokeTamoxifenTestingThickThinnessVascular Smooth MuscleWestern Worldatheroprotectivebiomarker panelcell dedifferentiationcell typecytokinefeedingin vivoindexinginhibitor/antagonistmacrophagemigrationneutralizing antibodynew therapeutic targetnovelnovel strategiesnovel therapeutic interventionpluripotencyreceptortherapeutic targettranscriptome sequencingvirtualwestern diet
项目摘要
Atherosclerosis is a progressive disease that is a leading cause of death in the Western world. Remarkably,
despite decades of research, there remain major ambiguities regarding the role of smooth muscle cells (SMC)
in lesion pathogenesis, as well as mechanisms that control plaque stability and the probability of plaque rupture
with possible myocardial infarction (MI) or stroke. The general dogma is that SMC are primarily involved in late
not early stage lesions, and that their primary role is atheroprotective by contributing to formation of a fibrous
cap. However, recent Nature Medicine studies by our lab involving simultaneous SMC-specific lineage tracing
and knockout (KO) of the stem cell pluripotency genes, Oct4 or Klf4 provided compelling evidence that SMC
play a much greater role in lesion pathogenesis than has been generally appreciated. Key findings include our
showing that: 1) >80% of SMC-derived cells within advanced lesions of ApoE-/- mice lack detectable expression
of typical SMC markers; 2) 30-40% of SMC-derived cells within both advanced mouse and human lesions lack
detectable SMC markers and have activated markers of MФs; and 3) SMC can have major beneficial or
detrimental effects on lesion pathogenesis depending on the nature of their phenotypic transitions. Thus, there is
a critical need to identify factors and mechanisms that promote beneficial changes in SMC phenotype. Studies in this
proposal will test the overall hypothesis that PDGFβR-dependent changes in SMC phenotype are atheroprotective and
that augmentation of the PDGFβR signaling pathway should be one of the primary therapeutic targets for treating
advanced atherosclerosis. This hypothesis will be tested in two specific aims. Aim 1 will test the hypothesis that PDGFβR-
dependent transitions in SMC phenotypic play a critical role in the development and progression of atherosclerosis. Aim
1a will extend our initial studies showing that SMC specific conditional PDGFβR KO at 6-8 weeks of age followed by 18
weeks of Western diet (WD) resulted in BCA lesions that were larger but virtually lacking SMC to include rigorous analysis
of indices of plaque stability and mechanisms for reductions in SMC number within lesions. Aim 1b will test the hypothesis
that SMC-specific conditional KO of PDGFβR results in detrimental transitions in SMC phenotype including increased
numbers of SMC-derived Lgals3+ foam cells (SMC-FC) and reduced numbers of SMC derived myofibroblasts (SMC-MF)
within the fibrous cap. Aim 2 will test the hypothesis that PDGFβR-signaling pathways confer atheroprotective effects
within advanced atherosclerotic lesions at least in part through inducing favorable changes in SMC phenotype. Studies
will test how SMC-specific or global genetic or pharmacologic inhibition (Aims 2a-2c) or augmentation (infusion of rPDGF-
DD, Aim 2d) of PDGFβR signaling in Western diet fed ApoE-/- mice with advanced atherosclerotic lesions impacts overall
lesion pathogenesis, indices of plaque stability, SMC phenotypic transitions, and the incidence of plaque rupture. Results
may lead to development of novel therapeutic approaches for reducing late stage clinical complications of atherosclerosis
by inducing SMC to undergo beneficial changes in phenotype-function that promote formation of a thicker and
mechanically more stable fibrous cap, thus reducing the probability of plaque rupture and a possible MI or stroke.
动脉粥样硬化是一种进行性疾病,在西方世界是导致死亡的主要原因。值得注意的是,
尽管经过了几十年的研究,但关于平滑肌细胞(SMC)的作用仍然存在重大的模糊
在病变发病机制中,以及控制斑块稳定性和斑块破裂概率的机制
可能患有心肌梗塞(MI)或中风。一般的教条是,SMC主要参与晚期
而不是早期病变,它们的主要作用是通过促进纤维的形成来保护动脉粥样硬化
帽子。然而,我们实验室最近进行的涉及SMC特定血统追踪的自然医学研究
和干细胞多潜能基因Oct4或Klf4的敲除(KO)提供了令人信服的证据,表明SMC
在病变发病机制中发挥的作用比人们普遍认识的要大得多。主要发现包括我们的
结果显示:1)ApoE-/-小鼠晚期皮损中80%的SMC来源细胞缺乏可检测到的表达
典型的SMC标志物;2)晚期小鼠和人类病变中30-40%的SMC来源的细胞缺乏
可检测到的SMC标志物和已激活的M-Ф标志物S;以及3)SMC可能具有主要的有益或
对病变发病机制的不利影响取决于其表型转换的性质。因此,有
迫切需要确定促进SMC表型有益变化的因素和机制。在这方面的研究
该提案将检验这一总体假设,即血管内皮生长因子βR依赖的SMC表型变化具有动脉粥样硬化保护作用
血小板衍生生长因子βR信号通路的增强应成为治疗的主要靶点之一
晚期动脉粥样硬化。这一假设将在两个具体目标上得到检验。目标1将检验以下假设:PDGFβR-
SMC表型的依赖性转变在动脉粥样硬化的发生和发展中起着关键作用。目标
1A将延长我们的初步研究,表明6-8周龄的SMC特异性条件性PDGFβR KO在18周龄后
几周的西方饮食(WD)导致了更大的BCA病变,但实际上缺乏SMC来进行严格的分析
斑块稳定性指标和斑块内SMC数量减少的机制。目标1b将检验假设
PDGFβR的SMC特异性条件性KO导致SMC表型的有害转变,包括增加
SMC来源的Lgals3+泡沫细胞(SMC-FC)数量和SMC来源的肌成纤维细胞(SMC-MF)数量减少
在纤维帽里。目的2验证血小板衍生生长因子β受体信号通路具有动脉粥样硬化保护作用的假设
在晚期动脉粥样硬化病变中,至少部分通过诱导SMC表型的有利变化。研究
将测试SMC特异性或全局遗传或药物抑制(目标2a-2c)或增强(注入rPDGF-
在西方饮食喂养的晚期动脉粥样硬化病变的ApoE-/-小鼠中,血小板衍生生长因子βR信号的Dd,Aim 2d)全面影响
病变发病机制、斑块稳定性指数、SMC表型转变和斑块破裂发生率。结果
可能导致开发新的治疗方法来减少动脉粥样硬化的晚期临床并发症
通过诱导SMC在表型功能上经历有益的变化,促进形成更厚的和
力学性能更稳定的纤维帽,从而降低斑块破裂和可能的心肌梗死或中风的可能性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gary K Owens其他文献
Gary K Owens的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gary K Owens', 18)}}的其他基金
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
- 批准号:
10652788 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
Role of Smooth Muscle Cell Insulin Resistance and Systemic Metabolic Dysfunction in Atherosclerosis Development and Late Stage Lesion Pathogenesis
平滑肌细胞胰岛素抵抗和全身代谢功能障碍在动脉粥样硬化发展和晚期病变发病机制中的作用
- 批准号:
10731723 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
Endothelial Cell to Mesenchymal Cell Transitions Play a Critical Biological Sex- and Aging-Dependent Role in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap
内皮细胞向间充质细胞的转变在 Acta2 动脉粥样硬化病变保护性纤维帽的形成和维持中发挥着关键的生物性别和衰老依赖性作用
- 批准号:
10355596 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Endothelial Cell to Mesenchymal Cell Transitions Play a Critical Biological Sex- and Aging-Dependent Role in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap
内皮细胞向间充质细胞的转变在 Acta2 动脉粥样硬化病变保护性纤维帽的形成和维持中发挥着关键的生物性别和衰老依赖性作用
- 批准号:
10542427 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Role of Metabolic Reprogramming in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap
代谢重编程在 Acta2 动脉粥样硬化病变保护性纤维帽形成和维持中的作用
- 批准号:
10441555 - 财政年份:2021
- 资助金额:
$ 64.71万 - 项目类别:
Role of Metabolic Reprogramming in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap
代谢重编程在 Acta2 动脉粥样硬化病变保护性纤维帽形成和维持中的作用
- 批准号:
10612042 - 财政年份:2021
- 资助金额:
$ 64.71万 - 项目类别:
Role of Metabolic Reprogramming in Formation and Maintenance of the Acta2+ Atherosclerotic Lesion Protective Fibrous Cap
代谢重编程在 Acta2 动脉粥样硬化病变保护性纤维帽形成和维持中的作用
- 批准号:
10292012 - 财政年份:2021
- 资助金额:
$ 64.71万 - 项目类别:
IL1beta signaling in SMCpromotes beneficial changes in late stage atherosclerotic lesion pathogenesis
SMC 中的 IL1β 信号传导促进晚期动脉粥样硬化病变发病机制的有益变化
- 批准号:
10331329 - 财政年份:2019
- 资助金额:
$ 64.71万 - 项目类别:
Defining SMC phenotypes critical in late stage atherosclerosis pathogenesis
定义在晚期动脉粥样硬化发病机制中至关重要的 SMC 表型
- 批准号:
10084307 - 财政年份:2018
- 资助金额:
$ 64.71万 - 项目类别:
Oct4 and Klf4 regulate microvascular SMC-pericyte plasticity, angiogenesis, and metabolic dysfunction
Oct4 和 Klf4 调节微血管 SMC-周细胞可塑性、血管生成和代谢功能障碍
- 批准号:
9919376 - 财政年份:2017
- 资助金额:
$ 64.71万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 64.71万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Studentship
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 64.71万 - 项目类别:














{{item.name}}会员




